Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 17 Ovarian Neoplasms 11 Neoplasms 8 Fallopian Tube Neoplasms 8 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasm Metastasis 6 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Glioma 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Recurrence 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Fanconi Anemia, Complementation Group D1 2 Cholangiocarcinoma 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

Cetuximab 5 pembrolizumab 3 Injections 3 Bevacizumab 2 taxane 1 ribociclib 1 pegylated granulocyte colony-stimulating factor 1 olaparib 1 fludarabine phosphate 1 fludarabine 1 encorafenib 1 dapagliflozin 1 cemiplimab 1 binimetinib 1 anlotinib 1 amivantamab 1 adagrasib 1 Pemetrexed 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Immunotherapy, Adoptive 1 IFL protocol 1 Folfox protocol 1 Fluorouracil 1 Filgrastim 1 Docetaxel 1 Cyclophosphamide 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Solid Tumors × olaparib × Clear all

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡